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Early identification and prognostic stratification of delayed
graft function following renal transplantation has significant
potential to improve outcome. Mass spectrometry analysis of
serum samples, before and on day 2 post transplant from
five patients with delayed graft function and five with an
uncomplicated transplant, identified aminoacylase-1
(ACY-1) as a potential outcome biomarker. Following assay
development, analysis of longitudinal samples from an initial
validation cohort of 55 patients confirmed that the ACY-1
level on day 1 or 2 was a moderate predictor of delayed graft
function, similar to serum creatinine, complementing the
strongest predictor cystatin C. A further validation cohort of
194 patients confirmed this association with area under
ROC curves (95% CI) for day 1 serum (138 patients) of 0.74
(0.67–0.85) for ACY-1, 0.9 (0.84–0.95) for cystatin C, and 0.93
(0.88–0.97) for both combined. Significant differences in
serum ACY-1 levels were apparent between delayed, slow,
and immediate graft function. Analysis of long-term follow-
up for 54 patients with delayed graft function showed a
highly significant association between day 1 or 3 serum
ACY-1 and dialysis-free survival, mainly associated with the
donor–brain–dead transplant type. Thus, proteomic analysis
provides novel insights into the potential clinical utility
of serum ACY-1 levels immediately post transplantation,
enabling subdivision of patients with delayed graft function
in terms of long-term outcome. Our study requires
independent confirmation.
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Renal transplantation provides clear benefits for patients
with end-stage kidney disease,1,2 and significant cost savings
compared with dialysis.3,4 In 2010, 16,151 renal transplants
were performed in the United States (http://optn.transplant.
hrsa.gov), and 2687 in the United Kingdom (http://www.
uktransplant.org.uk). However, early complications can
significantly impact clinical and economic outcomes, such
as delayed graft function (DGF) that affects B20% of
patients in the United States.5 A number of definitions of
DGF have been proposed6–8 with one commonly used being
the need for dialysis in the first week after renal
transplantation, other than for isolated hyperkalemia.
Although there are parallels with acute kidney injury, the
pathology underlying DGF is complex with contributions
from donor-derived factors, such as donor age and duration
of ischemia, and recipient factors such as ischemia–
reperfusion injury (IRI), immunological responses, and
immunosuppressant medications.9 Acute tubular necrosis
secondary to IRI is the predominant histological finding but
acute cellular or humoral rejection may occur concurrently,
and other pathologies are sometimes apparent histologically,
e.g., calcineurin inhibitor toxicity. Increasing use of organs
donated after circulatory death (DCD) and from extended
criteria donors10 has corresponded with an increase in the
incidence of DGF. DGF increases the risk of graft failure,
patient death, and death-censored graft failure by two-
to three-fold,11,12 and is associated with a number of
complications that contribute to reduced longer-term graft
survival, such as a poor transplant function at 1 year, arterial
hypertension, and acute rejection.13 Overall, DGF has
been associated with a 41% increased risk of graft loss at
just over 3 years.14
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Early identification, stratification, and increased under-
standing of DGF has significant potential to improve patient
management and outcomes,15 allowing fluid volume status
optimization, timely appropriate dialysis, tailoring of
therapies, and avoidance of unnecessary investigation and
treatment. There is increasing excitement about the potential
of clinical proteomics in identifying new biomarkers with
clinical impact,16 complementing promising markers
emerging from genomic-based studies. Urinary markers
currently under investigation in renal transplantation
include interleukin 18 and neutrophil gelatinase lipocalin,17
with tissue-associated markers including ICAM-1 and
VCAM.15,18 Unfortunately, in the majority of cases of
DGF, urine is not produced or may be mixed with residual
native renal output confounding analysis of any results,
and biopsied tissue is often only available once DGF is
established. Although serum neutrophil gelatinase lipocalin
and interleukin 18 have not shown promise,19 blood-borne
biomarkers would be ideal being readily accessible and
routinely used in hospital laboratories. However, biomarker
discovery with serum or plasma is challenging with only
22 proteins comprisingB99% of the total protein mass, and
the wide dynamic range of protein abundances spanning
410 orders of magnitude.20
In this study (Figure 1), we have compared serum proteins
pre- and postoperatively from patients undergoing renal
transplantation, with and without DGF, using our previously
optimized immunodepletion followed by label-free single-
dimensional liquid chromatography-tandem mass spectro-
metry analysis strategy.21 A key candidate marker of DGF was
identified as aminoacylase-1 (ACY-1). Following assay
development and validation, allowing the measurement of
ACY-1 in serum for the first time, the predictive use of ACY-1
for DGF as early as day 1 post transplant was confirmed.
Using follow-up data from a cohort of 194 transplant patients
where as expected DGF was associated with poor prognosis,
serum ACY-1 day 1 post transplant was shown to further
subdivide the 54 patients with DGF in terms of their long-
term outcome.
RESULTS
Patient groups
Examination of the patient groups (Figure 1, Table 1) shows
similar characteristics of cohorts 1 (the discovery and initial
validation group) and 2 (the larger validation group with
long-term outcome data), with the exceptions of proportion
of DCD transplants and the induction regimen, reflecting
changing clinical practice. DGF was diagnosed in 31.9% of
patients in cohort 1 and 28.4% of patients in cohort 2. Mean
age and cold ischemic time (CIT) were significantly higher in
the DGF groups in each cohort, as was warm ischemic time
(WIT) in cohort 2. The five DGF and five non-DGF patients
used for the initial proteomic discovery had no evidence of
calcineurin inhibitor toxicity or acute rejection and were
matched as closely as possible in terms of mean age, ethnicity
mix, CIT, WIT, and mean HLA mismatches at the A, B, and
DR loci, and immunosuppression regimens, differing slightly
in donor type (five DCD in the DGF group compared
with three DCD/two donation after brain death (DBD) in the
non-DGF group).
Mass spectrometry and candidate biomarker selection
Across all 20 samples (10 patients, two time points) used for
the initial mass spectrometry screen, 553 proteins with at
least two peptides (at least one of which was unique) were
identified and relative quantification determined (all proteins
listed and quantification data shown for selected proteins in
Supplementary Data—Proteins 1 and 2). On the basis of the
statistical significance (Po0.05), 34 candidates differentiated
between DGF and non-DGF groups either preoperatively,
postoperatively, or by pattern of change. These included
cystatin C demonstrating proof-of-principle. ACY-1 was
prioritized for further investigation, being undetectable
preoperatively but increasing markedly postoperatively,
particularly in the DGF group (Figure 2a).
Cohort 1
47 Leeds renal transplant
patients
(September 2008–July 2011);
665 longitudinal serum
samples
5 DGF patients and 5 non-DGF
patients (pre- and d2-post
transplant samples)
Candidate markers
Assay development
for ACY-1
Initial validation, longitudinal profiling; and
exploratory analysis of clinical
associations and predictive utility for DGF
compared with serum creatinine and cystatin
Cohort 2
194 Leeds renal transplant
patients
(December 2003–March 2006);
138 d1 and 177 d3 serum
samples
Independent confirmation of predictive utility.
Extended analysis including univariate/
multivariable analysis and prognostic utility
based on long-term outcome data
Serum proteomic
biomarker discovery
Figure 1 | Schematic showing the study design using samples
undergoing renal transplantation at the St James’s University
Hospital in Leeds. Following initial discovery of aminoacylase-1
(ACY-1) as a novel potential serum marker for delayed graft function
(DGF) using mass spectrometry, this was validated using
an immunoassay for ACY-1, and the performance as a predictive
marker assessed. Using serum samples from a further independent
cohort of patients, these results were confirmed and additionally the
association with long-term outcome in those patients with DGF
was examined.
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Table 1 | Demographic and clinical details for the DGF and non-DGF patients in cohorts 1 and 2, following renal transplantation
at the St James’s University Hospital in Leeds
Cohort 1 Cohort 2
DGF Non-DGF DGF Non-DGF
n¼ 15 total n¼ 32 total n¼ 55 total n¼ 139
6 Biopsied:
4 acute rejection
and 2 ATN
8 Biopsied: 6 acute
rejection and 2 mild
tubular injury P-value
40 Biopsied: 26 ATN,
8 rejection, and 6 both
ATN and acute rejection
16 Biopsied:
11 ATN, and
5 ATN and
acute rejection P-value
Number of patients,
and subgroups
9 Not biopsied:
5 calcineurin
inhibitor toxicity
and 4 assumed ATN
24 Not biopsied:
12 uncomplicated,
4 post transplant UTIs,
and 8 calcineurin
inhibitor toxicity NA
15 Not
biopsied:
all
assumed
ATN
123 Not
biopsied:
uncomplicated
transplants NA
Cause of ESRD (%)
Chronic pyelonephritis 0.0 18.8 0.573 14.5 12.2 0.719
Diabetes 6.7 3.1 12.7 10.1
Glomerulonephritis 33.3 31.3 32.7 30.9
Hypertension 6.7 12.5 5.5 10.8
Inherited 26.7 12.5 14.5 10.8
Other 20.0 15.6 7.3 5.0
Unknown 6.7 6.3 12.7 20.1
Ethnicity (%)
Asian 6.7 6.3 0.997 20.0 8.6 0.113
Black/African/Caribbean 6.7 6.3 1.8 1.4
Caucasian 86.7 87.5 58.2 61.9
Unknown 0.0 0.0 18.2 28.1
Transplant number (%)
1 86.7 78.1 0.807 80.0 90.6 0.247
2–4 13.3 21.9 18.2 7.9
Unknown 0 0 1.8 1.4
Pre-emptive (%)
No 100.0 78.1 0.128 96.4 92.8 0.338
Yes 0.0 21.9 1.8 6.5
Unknown 0 0 1.8 0.7
Mean time (months) on dialysis at
transplantation±s.d.a
32.8±20.7 32.2±25.0 0.941 54.6±40.4 36.5±36.4 o0.001
Mean age (years)±s.d. 52.4±12.1 40.6±14.1 0.007 50±13.9 46.2±14.9 0.046
Gender
% Male 73.3 59.3 0.547 37.0 62.6 0.002
Transplant types
% DBD 20.0 28.1 0.006 (0.123)# 57.4 61.9 o0.001
% DCD 80.0 34.3 38.9 13.7
% LD 0.0 37.5 3.7 24.5
Induction (%)
Alemtuzumab 26.7 31.2 0.983 0 0 NA
Basiliximab 73.3 68.7 100 100
Maintenance steroids used (%) 26.7 21.9 0.994 14.8 10.1 0.527
Mean ischemic time±s.d.
Cold (h:min) 16:06±03:11 10:24±06:08 0.002 16:42±04:48 13:48±08:18 0.019
Warm (min) 40±13 39±9 0.782 49.2±19.1 36.9±13.6 o0.001
Mean total HLA mismatch±sd 3.3±1.0 2.6±1.8 0.127 2.4±1.3 2.0±1.4 0.096
Abbreviations: ATN, acute tubular necrosis; DBD, donations after brain death; DCD, donations after circulatory death; DGF, delayed graft function; ESRD, end-stage renal
disease; HLA, human leukocyte antigen; LD, live donor; NA, not applicable; UTI, urinary tract infection.
P-values are provided for differences between the DGF and non-DGF groups in each cohort.
Details of biopsies performed, and other postoperative events (e.g., UTIs) were collected along with serum creatinine, tacrolimus concentrations, C-reactive protein
concentrations, and urinary protein/creatinine ratios. In addition, eight live donors were included in the study to check for the effects of surgery on marker levels (mean age
44.0±12.3, 37.5% male).
aExcludes pre-emptive transplants, for second and subsequent transplants, total time on dialysis aggregated; #P-value if LD excluded as rare in DGF.
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Serum concentrations of ACY-1 in cohort 1 and relationship
to clinical events
Using our in-house ELISA, data for serum ACY-1 broadly
supported the mass spectrometry data for the discovery
samples (Figure 2). ACY-1 was undetectable (o15.6 ng/ml)
in all pre-transplant samples in this set, and in cohort 1 as a
whole 43/47 patients had undetectable ACY-1 pre-transplant
with the remainder beingo50 ng/ml and with no significant
pre-transplant difference between DGF and non-DGF
groups. Of the 636 longitudinal samples analyzed, ACY-1
was detected in only 230 samples, predominantly in the
5 days post transplant. Similarly live donors exhibited no
ACY-1 concentrations (450 ng/ml) post surgery with 10/12
having undetectable ACY-1 concentrations, indicating
that serum ACY-1 concentrations were not affected by
surgery per se.
Examples of serum ACY-1 profiles with different clinical
courses are shown in Figure 3 (full data for all patients
including additional clinical events and measurements is in
Supplementary Data—Profiles). A peak in ACY-1 concentra-
tion (4200 ng/ml) was observed at p4 days post transplan-
tation in 10/15 patients with DGF (66.7%) but in only
6/32 (18.8%) non-DGF transplants, three of whom had an
uncomplicated clinical course immediately post transplant.
Longitudinal profiles of ACY-1 concentration did not follow
the trends seen in any of serum creatinine, cystatin C,
C-reactive protein, tacrolimus, or urinary protein/creatinine
ratio, with the exception of a peak in ACY-1 in one patient
suffering from tacrolimus toxicity with an extremely high
concentration of tacrolimus (trough level 33 ng/ml, intended
range 9–14 ng/ml). Importantly, there was no distinct peak in
serum ACY-1 in patients at the time of positive mid-stream
urinary cultures (n¼ 19; ACY-1o15.6–88.3 ng/ml), episodes
of postoperative dialysis, or at the time of biopsy-proven
rejection, with the exception of one patient where ACY-1
concentration peaked at 260 ng/ml 4 days before biopsy,
becoming undetectable by the time of the biopsy.
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Figure 3 | Examples of profiles for serum aminoacylase-1 (ACY-1), creatinine (Cr), and cystatin C concentrations longitudinally
following renal transplantation in three patients with different clinical courses. (a) Uncomplicated transplant, (b) delayed graft function
(a marked peak in ACY-1 concentration 4200 ng/ml was seen in 10/15 patients with DGF (66.7%) but only 6/32 (18.8%) non-DGF patients),
(c) acute rejection (AR; *) followed by two urinary tract infections (UTIs; k). The pre-transplant concentrations are shown as day 0. Full
profiles for all cohort 1 patients and associated clinical events and measurements are provided in Supplementary Data—Profiles.
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Figure 2 | Serum aminoacylase-1 (ACY-1) concentrations
preoperatively and on day 2 postoperatively in the delayed graft
function (DGF) and non-DGF groups used for initial biomarker
discovery (five patients per group). ACY-1 as measured by (a) mass
spectrometry label-free intensity and (b) subsequent enzyme-linked
immunosorbent assay for the same samples. LFQ, label-free
quantification. A–J indicate different patients.
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Serum concentrations of ACY-1 post transplant in cohort 2
compared with cohort 1
In cohort 2 (the larger final validation set), of the 138
day 1 samples, 30 patients had undetectable serum ACY-1
concentrations (4/42 (9.5%) DGF patients, 26/96 (27.1%)
non-DGF), with a similar pattern being seen (18.8% vs.
42.6%, respectively) for day 3 values also (data not shown).
In both cohorts, day 1 concentrations of ACY-1 were
significantly different between the DGF and non-DGF groups
although overlapping (Figure 4a and b). When non-DGF
patients from the larger cohort 2 were categorized on the
basis of creatinine reduction ratio (CRR¼ (day 0 creatinine
minus day 7 creatinine)/day 0 creatinine),17,22 significant
differences in day 1 serum ACY-1 (Figure 4c) between
patients categorized as slow graft function (CRRo0.7 ) and
immediate graft function (CRRX0.7) were seen with an
increasing trend from immediate graft function to slow graft
function to DGF, demonstrating a relationship between the
rate of graft function improvement and ACY-1. Similar
results were also seen for day 3 serum ACY-1 concentrations
(data not shown).
Serum ACY-1 associations and predictive utility for DGF
For initial exploratory examination of the predictive utility in
cohort 1, ACY-1 and cystatin C concentrations for days 1 or
2 were combined as one time point (n¼ 35). The area under
the receiver operating characteristic (ROC) curve (AUC) for
day 1/2 ACY-1 predicting DGF was 0.74, with corresponding
figures for creatinine and cystatin C of 0.79 and 0.92,
respectively. ACY-1 and cystatin C combined improved
the AUC to 0.94 (Figure 5a). In cohort 2, the AUC for
day 1 ACY-1 was 0.77 with corresponding figures for creati-
nine and cystatin C of 0.75 and 0.9, respectively, with the
latter improving to 0.93 if combined with ACY-1 (Figure 5b).
Data-derived optimum cut-points for day 1 serum ACY-1
and cystatin C in cohort 2 (Table 2) show high specificity and
sensitivity, respectively. The optimum cut-point from
the combination of both through a logistic regression
model provide higher sensitivity and similar specificity, as
is apparent through the increased Youden index23 (0.71 vs.
0.43 and 0.64; Table 2).
Using the larger final validation cohort 2, significant
associations were observed between serum ACY-1 concentra-
tion and biopsy-proven acute tubular necrosis, transplant
type, age at transplantation, CIT, total WIT, and day 1 serum
creatinine and cystatin C (Table 3). On univariate analysis,
day 1 serum ACY-1, cystatin C and creatinine concentrations,
and transplant type, WIT and total HLA mismatch were all
significantly associated with the development of DGF
(Table 4). A multivariable logistic regression model for the
prediction of DGF was developed incorporating day 1 serum
ACY-1, creatinine and cystatin C concentrations, patient age
and gender, transplant type (DBD, DCD), HLA mismatch,
CIT, WIT, and initial steroid use. Day 1 serum ACY-1 was
significant using the likelihood ratio test (P¼ 0.013; Table 4)
and maintained a high, if reduced, odds ratio compared with
univariate analysis. Cystatin C was the only other indepen-
dent predictor of DGF in this model (Po0.0001).
A risk assessment plot for this full multivariable
model (new model) and the model without ACY-1
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Figure 4 | Serum aminoacylase-1 (ACY-1) concentrations on day 1
post transplant in the delayed graft function (DGF) and non-
delayed graft function groups. (a) Cohort 1 and (b) cohort 2, and
(c) on day 1 post renal transplant in patients in cohort 2 with DGF,
slow graft function (SGF), and immediate graft function (IGF). Tukey’s
box plots show median values and interquartile ranges with
significant differences between the groups indicated as determined
by the Mann–Whitney test.
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(reference model) are shown in Supplementary Figure S1
online for patients with and without DGF. Neither model
showed evidence of a lack of goodness of fit (Supple-
mentary Table S1 online) nor were the AUCs signifi-
cantly different as could be anticipated from bootstrap
confidence intervals (CIs; P¼ 0.345). The greatest predic-
tive benefit was shown to be for those patients who did not
have DGF where 47.4% (95% CI 24.5–70.2%) of patients
have a reduced risk according to the new model (in
agreement with the high NPV in Table 2). There was also
a reduction in the risk for those patients with DGF and
this resulted in an overall net reclassification index with a CI
that contains zero. The integrated discrimination index
for those without DGF was 0.0196 (95% CI 0.004–0.036),
further demonstrating the increase in negative predictive
value of ACY-1.
Serum ACY-1 and outcome
Serum ACY-1 concentrations on day 1 post transplant
showed no correlation with length of DGF, serum creatinine,
estimated glomerular filtration rate (modified MDRD), and
urinary protein/creatinine ratio at 1 year (cohorts 1 and 2).
Similarly analysis of longer-term follow-up data in
cohort 2 showed no significant association between ACY-1
concentration on day 1 post transplant and overall
or dialysis-free survival.
Given the significant association of ACY-1 with DGF and
the significantly increased serum concentrations seen in both
DBD and DCD transplant types with DGF (Figure 6), a
subgroup analysis using the DGF group only (n¼ 54)
was undertaken and showed an association between day 1/3
(day 3 used if day 1 values unavailable) serum ACY-1 and
dialysis-free survival in DGF patients (day 1 hazard
ratio¼ 0.993, 95% CI (0.988, 0.999), P¼ 0.0174). Reflecting
hazard ratioso1, survival curves showed a significant
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Figure 5 | Receiver operating characteristic curves for the prediction of delayed graft function, each showing serum aminoacylase-1
(ACY-1), creatinine (SCr), cystatin C (CystC), and ACY-1 combined with cystatin C. (a) Cohort 1 results—days 1/2 post transplant
(n¼ 47 but n¼ 35 for ACY-1 and CystC); (b) Cohort 2 results—day 1 post transplant (n¼ 194 but n¼ 138 for ACY-1 and 128 for CystC).
AUC, area under the curve; CI, confidence interval.
Table 2 | Estimates and 95% confidence intervals for
measures of diagnostic accuracy for ACY-1, cystatin C,
serum creatinine, and combined serum ACY-1 and cystatin C
for optimal cut-offs as determined in cohort 2 data for
day 1 measurements (for serum Cr the additional condition
that specificity was 450% was applied)
Estimate LCI UCI
ACY-1 (cut-off 200 ng/ml)
Sensitivity 54.76 39.71 69.81
Specificity 88.54 82.17 94.91
PPV 67.65 51.92 83.37
NPV 81.73 74.30 89.16
OR 9.35 3.90 22.40
Youden index 0.43
Cystatin C (cut-off 3.3mg/ml)
Sensitivity 87.18 76.69 97.67
Specificity 76.40 67.58 85.23
PPV 61.82 48.98 74.66
NPV 93.15 87.36 98.95
OR 22.02 7.64 63.47
Youden index 0.64
Serum creatinine (cut-off 550mmol/l)
Sensitivity 79.63 68.89 90.37
Specificity 55.56 46.88 64.23
PPV 43.43 33.67 53.20
NPV 86.42 78.96 93.88
OR 4.89 2.31 10.35
Youden index 0.35
ACY-1 þ cystatin C (cut-off probability 0.2)
Sensitivity 92.31 83.94 100
Specificity 78.65 70.14 87.16
PPV 65.45 52.89 78.02
NPV 95.89 91.34 100
OR 44.21 12.26 159.37
Youden index 0.71
Abbreviations: ACY-1, aminoacylase-1; LCI, lower confidence interval; NPV, negative
predictive value; OR, odds ratio relative to diagnostic cut-off; PPV, positive
predictive value; UCI, upper confidence interval.
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Table 3 | Associations between day 1 serum ACY-1 concentration and relevant variables in cohort 2 (n¼ 138 with day 1
samples)
Characteristic Subgroup N Median (range) P-value*
Gender M 90 43.4 (15.6, 7324.5)
F 48 74.5 (15.6, 7207.2) 0.1277
Age at transplantation (years) — 138 0.30 0.0003
Transplant type DBD 79 48.3 (15.6, 5905.3)
DCD 29 365.6 (29.3, 7324.5)
LD 30 15.6 (15.6, 156.1) o0.0001
CIT (min) — 138 0.25 0.0033
Total WIT (min) — 138 0.53 o0.0001
Total HLA mismatch 0, 1, and 2 82 50.7 (15.6, 5905.3)
3, 4, 5, and 6 56 76.2 (15.6, 7324.5) 0.1261
Initial steroid use Y 15 72.3 (15.6, 1094.2)
N 123 53.2 (15.6, 7324.5) 0.9397
DGF Y 42 253.7 (15.6, 7324.5)
N 96 33.6 (15.6, 864.1) o0.0001
Biopsy proven AR Y 11 66.3 (15.6, 1094.2)
N 127 53.4 (15.6, 7324.5) 0.6354
Biopsy proven ATN Y 29 143.9 (15.6, 7324.5)
N 109 44.0 (15.6, 1225.1) 0.0007
Both ATN and AR on biopsy Y 4 140.8 (18.8, 511.1)
N 134 53.7 (15.6, 7324.5) 0.5965
Serum creatinine day 1 (mmol/l) — 130 0.25 0.0050
Serum cystatin C day 1 (mg/ml) — 128 0.41 o0.0001
Abbreviations: ACY-1, aminoacylase-1; AR, acute rejection; ATN, acute tubular necrosis; CIT, cold ischemic time; DBD, donation after brain death; DCD, donation after
cardiac death; DGF, delayed graft function; F, female; HLA, human leukocyte antigen; LD, live donor; M, male; N, no; WIT, warm ischemic time; Y, yes.
*Spearman’s rank correlation coefficient and P-value if a single continuous variable, or median (range) and P-value from Wilcoxon–Mann–Whitney test or Kruskal–Wallis
test if comparing two or three subgroups.
‘Initial steroid use’ refers to whether patients received maintenance oral prednisolone as part of their initial daily immunosuppression regime. Biopsy results—a total
of 32 of these 138 patients had biopsies, and therefore the N category for the biopsy results includes those who did not undergo a biopsy.
Table 4 | Univariate and multivariable analysis of factors associated with delayed graft function in cohort 2 as determined by
logistic regression
Univariate Multivariable
Factor Level Odds ratio 95% CI P-value Odds ratio 95% CI P-value
Gender Male 1 1
Female 0.901 (0.456, 1.780) 0.7645 0.888 (0.223, 3.377) 0.8612
Age at transplantation (years) — 1.015 (0.992, 1.039) 0.2085 1.000 (0.959, 1.043) 0.9871
Transplant type DBD 1 1
DCD 3.066 (1.457, 6.453) 0.0032 0.730 (0.086, 6.181) 0.7724
CIT (min) — 1 (0.998, 1.001) 0.5720 1.000 (0.997, 1.003) 0.8496
Total WIT (min) — 1.040 (1.017, 1.064) 0.0007 1.043 (0.991, 1.097) 0.1040
Total HLA mismatch 0, 1, and 2 1 1
3, 4, 5, and 6 2.500 (1.255, 4.979) 0.0091 1.679 (0.415, 6.798) 0.4676
Initial steroid use N 1 1
Y 1.239 (0.424, 3.618) 0.6949 2.465 (0.290, 20.99) 0.4089
Serum ACY-1 day 1 (per increase 1mg/ml) — 31.17 (3.400, 285.7) 0.0023 13.82 (1.321, 434.9) 0.0115
Serum creatinine day 1 (per increase 1mmol/l) — 1.004 (1.002, 1.006) o0.0001 1.001 (0.997, 1.004) 0.7526
Serum cystatin C day 1 (per increase 1mg/ml) — 5.536 (2.775, 11.05) o0.0001 6.865 (2.678, 17.60) o0.0001
Abbreviations: ACY-1, aminoacylase-1; CI, confidence interval; CIT, cold ischemic time; DBD, donation after brain death; DCD, donation after cardiac death; HLA, human
leukocyte antigen; N, no; WIT, warm ischemic time; Y, yes.
‘Initial steroid use’ refers to whether patients received maintenance oral prednisolone as part of their initial daily immunosuppression regime. P-values from Wald test for all
variables other than multivariable ACY-1 day 1, where likelihood ratio test P-value is more appropriate because of larger relative odds ratio.
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negative association (Po0.001) between serum ACY-1
day 1/3 post transplant in patients with DGF and risk of
returning to dialysis within 5 years from transplantation,
which was not seen in the non-DGF group (Figure 7a and b).
The subdivision of patients with DGF into two groups based
on serum ACY-1 concentration on day 1 post transplant
produces groups of similar size and although the number of
events (n¼ 10 returning to dialysis) is small, the differences
remain striking. No similar associations with outcome
were observed for serum cystatin C or creatinine in patients
following DGF. Formal multivariable analysis was not
statistically valid given the low number of events and
numbers of variables, but extensive examination of the
clinical data detected no factors that differed between the
high and low-ACY-1 subgroups of DGF patients, which could
be linked to the differences in outcome with the possible
exception of donor type. Within the DGF patients only, a
marked difference in dialysis-free survival was seen with DBD
type transplants accounting for 9/10 events (Figure 7c and d)
and within the DBD type transplant patients in the
DGF group, a clear difference in outcome based on ACY-1
serum concentrations days 1/3 post transplant was seen
(Figure 7e).
Retrospective analysis of the 15 patients with DGF
in cohort 1 also suggested an association of ACY-1 with
outcome. Although no graft failure and return to dialysis
events have yet occurred, three patients appear to have failing
transplants with estimated glomerular filtration rates of 10.8,
16.1, and 13.6. Defining these as a poor outcome group
and generating a contingency table classifying patients by
outcome and ACY-1 (Supplementary Table S2 online), no
evidence of a significant association (P¼ 0.506) is seen.
However, for ACY-1X200 the odds of having a poor
outcome are 1:8, whereas if ACY-1o200 the odds of a
poor outcome are 2:3. A conditional maximum likelihood
estimate of the odds ratio is calculated to be 0.215 (95%
CI 0.003–5.545), suggesting an association with outcome
analogous to that seen in cohort 2, and the lack of a
significant test result is probably due to a combination of low
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Figure 6 | Serum aminoacylase-1 (ACY-1) concentrations (log
scale) on day 1 or 3 post transplant for delayed graft function
(DGF) and non-DGF patients in cohort 2, separated by donor
type. Medians are indicated by the horizontal bar. Within the non-
DGF group, significant differences were seen between each donor
type (Po0.001) with median values of 35.2, 107, and 15.6 ng/ml for
donation after brain death (DBD), donation after cardiac death (DCD),
and live donor (LD), respectively, and similarly within the DGF group
between DBD and DCD groups with median values of 70.3 and
483.2 ng/ml. Comparing DGF and non-DGF groups, significantly
higher ACY-1 concentrations were seen in patients receiving
transplants from both DBD (P¼ 0.023) and DCD (Po0.001).
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Figure 7 | Kaplan–Meier estimates of survival function for
dialysis-free survival post renal transplant in cohort 2 separated
by salient characteristics, where median follow-up was 5.93
years with a range of 0.02–7.90 years. (a) Delayed graft function
(DGF) and (b) non-DGF patients separated by serum concentrations
of aminoacylase-1 (ACY-1) on day 1 post transplant (or day 3 if no day
1 measurement was available). Numbers of events were: 1/28 (3.6%)
with ACY-1X200 and 9/24 (37.5%) with ACY-1o200 for DGF patients,
and 2/16 (12.5%) with ACY-1X200 and 5/89 (5.6%) with ACY-1o200
for non-DGF patients. (c) DGF and (d) non-DGF patients separated by
donor type (donation after cardiac death (DCD) and donation after
brain death (DBD)). Numbers of events were: 1/21 (4.8%) for DCD and
9/31 (29%) for DBD within the DGF patients, and 1/19 (5.3%) for DCD
and 6/86 (7%) for DBD in the non-DGF group. (e) DGF patients with
donor type DBD separated by ACY-1 concentration (as above).
Numbers of events were: 0/9 (0%) for DBD/ACY-1X200 and 9/22
(40.9%) for DBD/ACY-1o200. Reasons for return to dialysis included
recurrent focal segmental glomerular fibrosis, vascular rejection, and
chronic scarring on biopsy.
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power in a small sample and the more limited amount of
follow-up time.
DISCUSSION
This study clearly illustrates the potential of proteomics in
biomarker discovery and providing new insights into
underlying pathophysiology. Relatively little is known
about ACY-1, a zinc-binding homodimeric cytoplasmic
protein with a predicted monomeric mass of 45.8 kDa.24
In eukaryotic cells, 50–80% of all cellular proteins are acylated
at the N terminus, a co- or post-translational modification
that can affect protein function and stability. ACY-1 catalyzes
the hydrolysis of N-acetylated peptides, particularly the
N-acetylated neutral aliphatic amino acids, releasing free
amino acids for protein synthesis.25 The highest levels of
expression and activity are found in the kidney followed by
the liver, brain, skeletal muscle and pancreas, and low
expression in several other organs.24,26–29 Pan-tubule and
predominantly proximal tubule ACY-1 expression has been
shown in pig26 and human kidneys, respectively,28 with a
proposed role in amino-acid salvage.30 An inborn error of
metabolism with variable neurological features has been
associated with ACY-1 mutations, with effects on ACY-1
expression and activity depending on the mutation31 and
increased urinary N-acetylated amino acids.27 Located on
chromosome 3p21.1, a role as a tumor suppressor gene has
been proposed in both renal and lung cancers.24,32,33
The low or undetectable serum ACY-1 concentrations
pre-transplantation and the absence of any increase with
infection, or postsurgery in live donors, suggests the post
transplant elevation of ACY-1 in DGF is not simply due to
impaired renal clearance or a consequence of inflammation.
DGF is complex with multiple risk factors and underlying
mechanisms involving various cells including tubules and
the vasculature, from preprocurement to the postoperative
period.9,34 Assuming a renal tubular source, the increased
serum ACY-1 in many cases of DGF could reflect the extent
of tubular damage and this is supported by the association
with acute tubular necrosis (although the number of biopsies
was small) and the trend in serum ACY-1 concentrations
from uncomplicated transplants through slow graft function
to DGF. Conversely, the relationship between higher ACY-1
and better outcome following DGF may indicate increased
synthesis and a role in the repair process, potentially via
effects on amino-acid availability for protein synthesis.
The relatively high specificity but low sensitivity of this
marker for DGF may indicate different DGF subgroups with
different pathologies and outcomes. ACY-1 was one of 75
urinary proteins changing significantly in rats treated with
cyclosporine or sirolimus (but not tacrolimus)-treated rats,35
and ACY-1 forms adducts with the biologically active
metabolite generated in the kidney from mycophenolate
mofetil,36 proposed to be involved in organ toxicity.
However, we found no links with calcineurin inhibitor
toxicity or mycophenolate mofetil. Interestingly analysis of
serum samples from 22 patients with AKI, 10 of whom were
within 3 days of diagnosis, showed serum ACY-1
concentrations all o60 ng/ml (data not shown), possibly
indicating that whether reflecting damage or repair or any
possible underlying IRI, it is very specific to a pathological
process encountered primarily in certain transplant situations
and/or only occurs under the more extreme and extensive
ischemic/hypoxic conditions at that time. This is also
supported by the marked differences in serum ACY-1
between the DBD, DCD, and LD transplants.
In terms of markers for DGF, combining gene expression,
particularly in chemokines CCL19 and 21 and proteasome
subunits PSMB8 and 10, in zero-hour biopsies from deceased
and live donor grafts, with relevant clinical factors, has
resulted in AUC values of 0.74 for DGF and 0.93 for acute
rejection.37 Expression of RANTES and CCR1/CCR2 in
biopsies from patients with DGF has also been reported to be
associated with graft function at 1 year post transplantation
and later.38 Several existing markers of use in AKI have also
been examined39,40 but tissue KIM-1, for example, doesn’t
correlate with DGF,41 whereas urinary neutrophil gelatinase
lipocalin and interleukin 18 have some predictive value for
DGF17,42 but no correlation with long-term function.43 Day 1
serum neutrophil gelatinase lipocalin concentrations had
no predictive value for DGF but similar to our study,
serum cystatin C had an AUC of 0.83.17 Our specificity
(88.5%) and negative predictive values (81.7%) for ACY-1 in
relation to DGF are high enough to potentially contribute
to biomarker panels. Clearly serum cystatin C, which directly
reflects renal function, is superior to ACY-1 in predicting
DGF early with AUC similar to the 0.96 seen in a
meta-analysis of its use in predicting AKI in various clinical
settings.44 However, using both ACY-1 and cystatin C is
slightly better on day 1 with ACY-1 having higher specificity
and if a more sensitive ACY-1 assay was developed, further
discrimination by ACY-1 may be possible. However, the
major benefit of ACY-1 may be its apparent prognostic utility
within the DGF patient group, although yet to be confirmed
in further independent studies.
Further mechanistic insight may be apparent from gene
expression studies in mouse models of IRI.45 Sphingosine
kinase-1 catalyzes the formation of sphingosine-1-phosphate
that has been implicated in protection/repair in renal
IRI46–48, differs between grafts classified by function,49 and
is reported to interact with ACY-1 (refs 32,50). Inflammatory
and immune-response genes in donor biopsies have been
predominantly associated with IRI and DGF, with integrated
systems biology analysis approaches being proposed to
provide further insight.15 A recent comparison of DGF and
non-DGF pre-implantation biopsies found no significant
clustering of pathways until the DGF group was subclassified
on the basis of renal function during the first year, when
genes implicated in T-cell activation, antigen presentation,
and cell adhesion were associated with subsequent poorer
function.49 This subclassification of DGF patients is
analogous to the situation with ACY-1 in our study,
where clear elevations in serum ACY-1 post transplant are
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seen in only about two-thirds of patients with DGF. This may
imply different underlying pathophysiological subgroups and
also demonstrates the prognostic value of ACY-1 within the
DGF patient group. Although several studies report a higher
frequency of DGF with DCD donor type, importantly our
examination of donor type confirms the lack of effect of DGF
on outcomes in the DCD transplant recipient group despite
prolonged periods of warm ischemia51–53 but the detrimental
effect of DGF on outcome in DBD patients.53,54 From animal
models, major systemic effects of brain death such as
catecholamine release and hypotension and subsequent
activation of proinflammatory mediators/cytokine response
in donor organs which then provokes further host responses
following transplantation have been proposed.55 Different
underlying pathologies responsible for the DGF with the
different donor types have been discussed with the possibility
of pre-existing or pre-terminal conditions, resulting in less
reversible changes with DBD organs than the acute
tubular necrosis encountered following terminal warm
ischemia in the DCD donors.53 This would align with one
of our hypotheses that ACY-1 is essentially a marker of
repair/response to damage with those patients showing lower
response having poorer outcome, as can be seen in a
subgroup of DBD donor type transplant patients with lower
ACY-1 concentrations immediately post transplant.
This study illustrates the significant potential that clinical
proteomics can have in biomarker discovery. The identifica-
tion of serum ACY-1 with fair predictive value in the
immediate postoperative period, and, most importantly, the
potential ability to stratify patients within the DGF group,
in particular in the DBD transplant, in terms of long-term
outcome, may contribute to the development of outcome
signatures, enabling better patient stratification and post
transplant management. Further larger studies are needed
to confirm these findings together with development of a
more sensitive assay and biological studies to understand the
source and regulation of ACY-1 expression in DGF and its
relationship to specific underlying pathophysiology.
MATERIALS AND METHODS
Patient groups and study design
Patients were consented before undergoing renal transplantation
(Figure 1). Venous blood samples were obtained prospectively
pre-transplant and longitudinally at least three times a week post
transplant (mean 14 samples/patient). Blood was collected and
serum obtained according to stringent standardized procedures.
Patient cohort 1 included 55 patients (665 samples; 47 renal
transplant patients and 8 live donors), 15 of whom had DGF (based
on the definition of needing dialysis in the first week after renal
transplantation other than for isolated hyperkalemia), and cohort 2
included 194 patients (138 with day 1 and 177 with day 3 samples),
55 of whom had DGF (Figure 1). Initial biomarker discovery was
carried out using serum samples from five patients in cohort 1 with
DGF and five with no complications, matched clinically as far as
possible, comparing samples taken pre-transplant and at day 2 post
transplant (20 samples in total). Validation of the initial findings was
then undertaken using samples from cohort 1 followed by cohort 2
with numbers being determined based on statistical power (Supple-
mentary Methods online ). For example, 10 DGF and 25 non-DGF
patients with day 1/2 ACY-1 measurements gave a power of 80% to
detect an AUC40.8 when Bonferroni correcting a 5% significance
test for two comparisons.56
Serum immunodepletion and sample preparation
The 20 serum samples in the discovery set were subjected to
immunodepletion using the Multiple Affinity Reagent System
14 column (Agilent, Stockport, UK) as previously described.21
Immunodepleted fractions were desalted and concentrated and the
resulting material was digested with trypsin using a modification21
of the filter-assisted sample preparation method (FASP).57
Label-free mass spectrometry
After acidification to a final concentration of 0.1% TFA, peptide
samples were block randomized by patient and analyzed (32 mg
injections per sample) using a Dionex UltiMate 3000 RSLCnano
system connected to LTQ Orbitrap Velos mass spectrometer
equipped with a Proxeon nanoelectrospray ion source.58 Samples
were injected directly onto an in-house 25-cm capillary emitter
column packed with 3.5-mm Kromasil C18 media. The total
acquisition time was 300min, the major part of the gradient being
3–25% ACN in 0.1% formic acid at the flow rate of 0.4ml/min.
Survey MS scans were acquired in the orbitrap with the resolution
set to 60,000. Up to the 20 most intense ions per scan were
fragmented and analyzed in the linear trap.
Data analysis and statistical methods
Label-free mass spectrometry data analysis was performed
using MaxQuant (v1.1.1.25).59 Proteins were identified using
Andromeda60 and the IPI human database (v3.75, 19/08/2010)
with the criteria of X2 peptides (at least one being unique),
and proteins identified from the decoy database and known
contaminants were removed. Differential expression between
and within patient groups was assessed using non-parametric
(Wilcoxon) significance tests on the changes in label-free
quantification intensity. The false discovery rate was estimated
using the q-value method.61
In the validation analysis, ROC curves were constructed to assess
predictive ability of serum ACY-1, creatinine, and cystatin C.62 The
area under the ROC curve was estimated and 95% CIs estimated
from 2000 bootstrap resamples. AUCs were compared using a
bootstrap significance test with the significance of differences
between bootstrap AUCs assessed using a normal approximation.
Risk assessment plots63 and summary statistics relating to the net
reclassification index and integrated discrimination index64,65 were
estimated using bespoke R functions and CIs estimated with 2000
bootstrap resamples. The association of relevant clinical factors
known to predict DGF was quantified and tested using univariate
logistic regression models, and multivariable logistic regression was
used to assess the independent predictive ability of ACY-1 for DGF
in models containing other relevant factors.66 In the multivariable
model likelihood ratio tests and Wald tests, and simple and profile
likelihood–based confidence intervals were contrasted due to the
large relative magnitude of some coefficients.67 The relationship
between ACY-1 and other marker concentrations and dialysis-free
survival was assessed using Cox proportional-hazard regression,
Kaplan–Meier survival functions, and the log-rank test. All statistical
tests were two-sided and all analyses were undertaken in the
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R environment for statistical computing (R Development Core
Team, Vienna, Austria).
Comparison with other analytes
Serum creatinine, C-reactive protein, tacrolimus, and urinary
protein/creatinine ratios were measured as per clinical protocol/
indication, and additionally serum creatinine and cystatin C were
measured in cohort 1 at the same time points used in the study.
ELISA development
ACY-1 concentrations were determined for the 980 serum samples
in both cohorts with samples being block randomized, using a
sandwich ELISA developed and validated in-house (Supplementary
Methods online) using rat anti-human ACY-1 monoclonal antibody
(clone 475626; R&D Systems; Minneapolis, MN) and polyclonal
goat anti-ACY-1 antibody (R&D Systems).
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